Cargando…
Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases
Infliximab is a monoclonal antibody directed against TNF-α. It has been approved for use in rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriatic arthritis and plaque-type psoriasis. In case reports, positive effects on pustular variants of psoriasis have also been repo...
Autores principales: | Mössner, Rotraut, Thaci, Diamant, Mohr, Johannes, Pätzold, Sylvie, Bertsch, Hans Peter, Krüger, Ullrich, Reich, Kristian |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2254657/ https://www.ncbi.nlm.nih.gov/pubmed/18239925 http://dx.doi.org/10.1007/s00403-008-0831-8 |
Ejemplares similares
-
Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment
por: Wolk, Kerstin, et al.
Publicado: (2023) -
Successful Treatment of a Patient with Pyoderma Gangrenosum, Plaque Psoriasis and Palmoplantar Pustulosis with Adalimumab
por: Chu, Yuqi, et al.
Publicado: (2022) -
Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study
por: Kromer, Christian, et al.
Publicado: (2019) -
Apremilast in Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Meta-analysis
por: Spencer, Riley K., et al.
Publicado: (2023) -
The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review
por: Sanchez, Isabelle M., et al.
Publicado: (2017)